coordin
project
author
contribut
equal
work
epidemiolog
respiratori
virus
rv
lung
transplant
recipi
ltr
relationship
rv
lung
function
acut
reject
ar
opportunist
infect
patient
well
known
perform
prospect
cohort
studi
collect
nasopharyng
swab
npss
asymptomat
ltr
season
chang
ltr
upper
respiratori
tract
infecti
diseas
urtid
lower
respiratori
tract
infecti
diseas
lrtid
ar
npss
analyz
multiplex
polymeras
chain
reaction
overal
npss
collect
patient
posit
rate
mean
followup
year
interquartil
rang
year
approxim
half
urtid
tracheobronch
case
caus
picornaviru
wherea
pneumonia
caus
mainli
paramyxoviru
four
nine
influenza
two
nine
ltr
lrtid
lung
function
chang
significantli
mo
p
mo
p
nest
casecontrol
analysi
ar
associ
rv
hazard
ratio
hr
pseudomona
aeruginosa
associ
lrtid
hr
cytomegaloviru
cmv
replic
diseas
associ
urtid
hr
previou
mo
associ
rv
aspergillu
spp
colon
infect
hr
conclus
document
high
incid
rv
infect
ltr
lrtid
produc
signific
lung
function
abnorm
associ
observ
ar
rv
p
aeruginosa
colon
infect
lrtid
cmv
replic
diseas
urtid
epidemiolog
respiratori
virus
rv
lung
transplant
recipi
ltr
relationship
rv
lung
function
acut
reject
ar
opportunist
infect
patient
well
known
perform
prospect
cohort
studi
collect
nasopharyng
swab
npss
asymptomat
ltr
season
chang
ltr
upper
respiratori
tract
infecti
diseas
urtid
lower
respiratori
tract
infecti
diseas
lrtid
ar
npss
analyz
multiplex
polymeras
chain
reaction
overal
npss
collect
patient
posit
rate
mean
followup
year
interquartil
rang
year
approxim
half
urtid
tracheobronch
case
caus
picornaviru
wherea
pneumonia
caus
mainli
paramyxoviru
four
nine
influenza
two
nine
ltr
lrtid
lung
function
chang
significantli
mo
p
mo
p
nest
casecontrol
analysi
ar
associ
rv
hazard
ratio
hr
pseudomona
aeruginosa
associ
lrtid
hr
cytomegaloviru
cmv
replic
diseas
associ
urtid
hr
previou
mo
associ
rv
aspergillu
spp
colon
infect
hr
conclus
document
high
incid
rv
infect
ltr
lrtid
produc
signific
lung
function
abnorm
associ
observ
ar
rv
p
aeruginosa
colon
infect
lrtid
cmv
replic
diseas
urtid
respiratori
virus
rv
increasingli
recogn
major
caus
morbid
mortal
hematopoiet
stem
cell
transplant
solid
organ
transplant
recipi
lung
transplant
recipi
ltr
popul
patient
constant
risk
rv
infect
continu
exposur
organ
extern
environ
potenti
respiratori
pathogen
impair
protect
mechan
graft
lung
hla
mismatch
presenc
signific
immunosuppress
sensit
contemporari
molecular
diagnost
techniqu
substanti
improv
allow
rapid
simultan
detect
wide
varieti
convent
emerg
rv
respiratori
sampl
present
techniqu
prefer
diagnost
tool
studi
rv
immunocompromis
patient
previou
studi
suggest
addit
direct
cytopath
tissueinvas
effect
rv
could
immedi
impact
function
transplant
lung
function
declin
rv
creat
inflammatori
environ
graft
lung
lead
local
system
microbi
determin
immun
modul
mdim
increas
alloand
autoimmun
respons
increas
suscept
opportunist
infect
result
develop
acut
reject
ar
although
conceptu
appeal
support
experiment
anim
studi
clinic
link
rv
indirect
effect
clearli
assess
key
limit
low
number
incomplet
event
heterogen
studi
popul
diagnost
tool
frequent
retrospect
natur
publish
report
aim
extens
prospect
cohort
studi
base
molecular
assay
character
epidemiolog
rv
associ
rv
lung
function
opportunist
infect
ar
begin
time
transplant
prospect
cohort
studi
perform
use
consecut
adult
patient
undergo
lung
transplant
hospit
univeristari
vall
dhebron
barcelona
spain
septemb
septemb
includ
patient
age
year
began
follow
patient
start
hospit
discharg
transplant
patient
follow
continu
septemb
death
detail
immunosuppress
prophylaxi
protocol
shown
tabl
data
collect
prospect
gener
hospit
microbiolog
histopatholog
databas
use
standard
protocol
studi
protocol
approv
vall
dhebron
ethic
committe
clinic
research
inform
consent
obtain
particip
extern
scientif
committe
consist
three
investig
two
lung
transplant
unit
specialist
hospit
universitario
polit
ecnico
la
fe
valencia
hospit
universitario
marqu
es
de
valdecilla
santand
one
infecti
diseas
specialist
hospit
universitario
de
octubr
madrid
member
wellestablish
independ
scientist
appoint
person
capac
extens
year
profession
multidisciplinari
experi
field
infect
ltr
expert
panel
appoint
annual
period
year
evalu
project
follow
databas
particip
interpret
result
panel
member
evalu
qualiti
data
collect
look
independ
random
number
case
focus
diseas
definit
patient
outcom
present
studi
submit
public
approv
expert
panel
studi
adher
principl
declar
helsinki
formul
world
medic
associ
ethic
statement
intern
societi
heart
lung
transplant
upper
respiratori
tract
infecti
diseas
urtid
defin
ill
caus
acut
infect
onset
sore
throat
rhinorrhea
hoars
lower
respiratori
tract
infecti
diseas
lrtid
defin
new
onset
short
breath
cough
sputum
rale
hypoxemia
andor
wheez
symptom
lrtid
associ
new
pulmonari
infiltr
chest
radiograph
chest
comput
tomographi
pneumonia
distinguish
tracheobronch
nosocomi
rv
infecti
diseas
refer
infecti
diseas
contract
patient
hospit
least
h
admit
patient
close
follow
frequent
phone
call
everi
week
check
health
statu
case
newonset
respiratori
tract
infect
symptom
fever
rhinorrhea
sore
throat
cough
dyspnea
sputum
myalgia
fatigu
thorac
pain
patient
instruct
contact
research
team
schedul
prompt
visit
h
outpati
clinic
lung
transplant
program
go
emerg
room
systemat
collect
nasopharyng
swab
npss
perform
patient
differ
set
patient
includ
asymptomat
patient
season
chang
around
calendarbas
season
chang
spring
summer
autumn
winter
patient
urtid
lrtid
biopsyproven
ar
urtid
control
assess
mo
first
episod
studi
period
investig
clinician
treat
patient
awar
result
viral
sampl
collect
npss
collect
special
medic
staff
use
standard
procedur
us
center
diseas
control
prevent
npss
taken
insert
swab
cm
nostril
access
posterior
nasopharynx
rotat
collect
secret
exfoli
nasopharyng
cell
npss
immedi
place
tube
contain
ml
viral
transport
medium
analyz
store
multiplex
nucleic
acid
amplif
test
nat
perform
depart
microbiolog
basel
univers
hospit
switzerland
vall
dhebron
univers
hospit
barcelona
spain
total
nucleic
acid
extract
sampl
use
autom
easymag
biom
erieux
marci
letoil
franc
qiasymphoni
qiagen
hilden
germani
system
accord
manufactur
protocol
mulitplex
nat
perform
use
seeplex
onestep
ace
detect
seegen
seoul
korea
respifind
pathofind
maastricht
netherland
follow
respiratori
virus
influenza
virus
b
respiratori
syncyti
virus
rsv
b
parainfluenza
virus
piv
rhinovirus
b
c
enteroviru
metapneumoviru
hmpv
coronavirus
bocaviru
adenoviru
rhinovirus
enterovirus
member
human
picornaviru
famili
detect
assay
use
term
picornaviru
describ
virus
although
sequenc
analysi
specif
assay
use
studi
reveal
almost
picornavirus
rhinovirus
human
rsv
hmpv
piv
member
paramyxovirida
famili
concurr
detect
one
rv
sampl
consid
singl
clinic
episod
data
collect
primari
secondari
outcom
statist
analysi
first
aim
studi
identifi
epidemiolog
clinic
manifest
season
rv
ltr
therefor
descript
analysi
perform
continu
variabl
express
median
rang
proport
calcul
percentag
patient
avail
data
present
median
interquartil
rang
iqr
continu
variabl
independ
ttest
use
compar
continu
data
chisquar
test
use
compar
categor
data
second
aim
studi
chang
allograft
function
forc
expiratori
volum
fev
mo
posit
rv
episod
evalu
mdim
effect
relat
rv
infect
biopsyproven
ar
cytomegaloviru
cmv
replic
diseas
aspergillu
spp
colon
infect
pseudomona
aeruginosa
colon
infect
surveil
strategi
perform
bronchial
biopsi
detect
ar
respiratori
cultur
p
aeruginosa
aspergillu
spp
blood
cmv
load
base
routin
screen
clinician
judgment
diagnosi
clinic
event
tabl
data
concern
clinic
cours
patient
prospect
collect
patient
clinic
followup
nest
casecontrol
analysi
use
condit
logist
regress
appli
differ
mdim
event
use
time
match
variabl
case
patient
event
biopsyproven
ar
cmv
replic
diseas
aspergillu
spp
colon
infect
p
aeruginosa
colon
infect
observ
followup
match
four
randomli
select
control
patient
without
event
cohort
followup
time
sinc
transplant
case
control
presenc
rv
observ
mo
prior
event
secondari
outcom
measur
evalu
mo
consid
advers
clinic
event
occur
soon
rv
infect
like
associ
infect
pvalu
consid
signific
data
analys
perform
stata
statacorp
colleg
station
tx
total
npss
collect
median
sampl
per
patient
minimum
maximum
posit
rate
systemat
collect
npss
differ
clinic
set
describ
tabl
sampl
collect
ltr
symptom
respiratori
infect
posit
case
wherea
asymptomat
ltr
season
chang
posit
case
tabl
season
pattern
observ
higher
incid
rate
found
winter
rv
per
patientyear
ci
autumn
rv
per
patientyear
ci
figur
tabl
paramyxoviru
piv
rsv
five
nine
influenza
two
nine
frequent
isol
virus
ltr
pneumonia
nine
incid
virus
statist
significantli
higher
associ
pneumonia
compar
picornaviru
one
nine
p
tabl
major
patient
symptomat
rv
infect
could
manag
outpati
tabl
paramyxoviru
influenza
infect
present
higher
risk
patient
urtid
signific
loss
fev
compar
preinfect
lung
function
mean
loss
ml
ci
ml
p
differ
signific
time
point
disappear
subsequ
patient
lrtid
lung
function
chang
significantli
compar
preinfect
valu
mo
ml
ci
ml
p
mo
ml
ci
ml
p
rv
infect
tabl
signific
spirometr
chang
observ
asymptomat
patient
compar
time
point
tabl
specif
rv
rv
coinfect
could
attribut
pronounc
clinic
effect
allograft
function
total
biopsyproven
case
ar
diagnos
case
cellular
ar
two
grade
grade
nine
grade
three
grade
two
humor
one
mix
grade
nest
casecontrol
studi
appear
ar
associ
presenc
rv
previou
mo
hazard
ratio
hr
ci
p
prospect
studi
perform
complet
examin
use
molecular
assay
epidemiolog
rv
ltr
demonstr
high
incid
rv
infect
rv
associ
direct
signific
clinic
impact
also
immedi
allograft
dysfunct
mdim
effect
contribut
significantli
develop
ar
opportunist
infect
strength
present
studi
resid
larg
lung
transplant
popul
analyz
lengthi
followup
throughout
season
compar
previou
literatur
area
asymptomat
patient
compar
symptomat
patient
urtid
lrtid
p
asymptomat
patient
compar
symptomat
patient
urtid
lrtid
p
ltr
rang
result
compar
data
publish
bridevaux
et
al
perform
larg
prospect
studi
among
ltr
elev
incid
describ
studi
rv
per
patientyear
probabl
associ
adopt
molecular
diagnost
provid
high
sensit
detect
emerg
virus
rv
caus
varieti
direct
effect
one
viru
exclus
associ
one
clinic
syndrom
although
rv
show
vari
tropism
respiratori
tract
studi
picornavirus
mainli
rhinoviru
coronavirus
influenza
viru
common
etiolog
agent
togeth
rv
account
microbiolog
confirm
symptomat
infect
rhinovirus
lead
caus
rv
infecti
diseas
ltr
find
agreement
knowledg
rv
primari
caus
acut
viral
respiratori
ill
studi
also
confirm
tropism
rhinoviru
lower
respiratori
tract
associ
lrtid
mainli
tracheobronch
interestingli
certain
virus
name
influenza
paramyxovirida
famili
includ
rsv
hmpv
piv
like
associ
lrtid
pneumonia
higher
hospit
rate
distribut
rv
infect
throughout
year
suggest
season
pattern
rv
circul
ltr
similar
circul
commun
rv
infect
studi
caus
picornavirus
known
circul
throughout
year
data
suggest
howev
clinic
sever
manifest
subsequ
impact
lung
allograft
function
driven
mostli
virus
circul
preferenti
winter
season
consequ
suggest
clinician
awar
circul
commun
rv
infect
vigilantli
maintain
knowledg
epidemiolog
among
ltr
moreov
effect
prophylaxi
treatment
involv
vaccin
antivir
therapi
would
need
urgent
rv
influenza
paramyxovirus
care
collect
clinic
data
demonstr
rv
infect
present
asymptomat
ltr
consist
mostli
picornavirus
coronavirus
note
asymptomat
rv
infect
associ
signific
declin
lung
function
measur
fev
mo
followup
contrast
rv
detect
significantli
higher
proport
symptomat
patient
urtid
lrtid
includ
broader
rang
agent
probabl
highlight
potenti
role
inflamm
transient
fev
declin
importantli
increas
sever
clinic
present
upper
lower
respiratori
tract
increas
impact
lung
function
becam
appar
signific
declin
mo
patient
lrtid
contrast
previou
report
studi
could
demonstr
differ
rv
exert
differ
effect
allograft
function
probabl
due
sampl
size
rv
increasingli
recogn
caus
communityacquir
infect
differ
hospit
outbreak
describ
exact
role
rv
nosocomi
acquisit
well
known
notabl
studi
found
rv
infect
acquir
hospit
admiss
immunosuppress
patient
rv
also
shown
caus
protract
clinic
diseas
viral
shed
keep
previou
report
studi
demonstr
prolong
shed
picornavirus
coronavirus
may
sourc
nosocomi
transmiss
concern
data
emphas
need
guidelin
manag
nosocomi
rv
relationship
rv
infect
ar
clearli
establish
present
studi
includ
acut
phase
viral
infect
relat
clinic
present
followup
period
mo
despit
rel
small
sampl
size
ar
first
prospect
studi
suggest
trend
hr
ci
p
toward
signific
clinic
link
rv
infect
biopsyproven
ar
lung
although
pathogenesi
link
well
understood
probabl
relat
respons
circul
leukocyt
initi
acut
viral
replic
induc
variou
inflammatori
signal
includ
alloreact
cytokin
releas
damag
parenchyma
infiltr
transplant
organ
bacteri
fungal
superinfect
danger
complic
rv
infect
studi
aim
analyz
relationship
rv
p
aeruginosa
latter
especi
problemat
pathogen
ltr
epidemiolog
data
collect
vitro
anim
model
suggest
role
rv
infect
facilit
colon
infect
p
aeruginosa
nevertheless
first
prospect
studi
reveal
rv
infect
involv
lower
respiratori
tract
ltr
predispos
patient
p
aeruginosa
isol
hr
ci
p
although
statist
control
effect
result
investig
support
notion
immunomodulatori
effect
cmv
well
known
may
predispos
patient
sever
opportunist
infect
contrast
observ
urtid
may
favor
cmv
replic
diseas
hr
ci
p
result
report
may
differ
interpret
patient
epidemiolog
exposur
rv
could
trigger
cmv
replic
rv
could
surrog
immunosuppress
state
host
suscept
cmv
rv
infect
previou
studi
suggest
rv
infect
may
risk
factor
subsequ
aspergillu
spp
infect
studi
statist
associ
found
probabl
statist
limit
relat
low
incid
aspergillosi
secondari
effect
antifung
prophylaxi
regimen
interpret
posit
test
asymptomat
patient
difficult
publish
data
longterm
consequ
interestingli
studi
associ
observ
asymptomat
statu
indirect
effect
ar
subsequ
bacteri
fungal
superinfect
probabl
asymptomat
detect
ltr
associ
use
molecular
techniqu
increas
viral
diagnost
rate
detect
minim
amount
copi
number
rv
moreov
asymptomat
detect
ltr
could
result
complex
balanc
exist
immunosuppress
inflammatori
respons
rv
manifest
asymptomat
statu
calcineurin
inhibitor
weaken
lymphocytemedi
immun
respons
previou
studi
use
quantit
evalu
immunosuppress
concomit
viral
screen
ltr
found
elev
tacrolimu
level
risk
factor
rv
infect
cohort
howev
associ
observ
median
calcineurin
inhibitor
level
clinic
present
studi
limit
first
collect
npss
howev
painless
practic
widespread
use
compar
sensit
nasopharyng
aspir
bronchoalveolar
lavag
detect
major
rv
second
possibl
miss
clinic
signific
viral
infect
methodolog
strategi
use
prospect
studi
probabl
error
unlik
infect
rate
highest
describ
medic
literatur
third
spirometr
outcom
evalu
accord
clinic
lung
allograft
surveil
without
protocol
rv
sampl
therefor
miss
function
test
like
bias
observ
declin
fev
fourth
small
sampl
size
patient
although
larg
ltr
popul
mdim
event
statist
analys
show
wide
ci
nonetheless
strongli
suggest
exist
real
associ
ltr
popul
last
median
incub
period
rv
day
statement
base
limit
evid
therefor
prefer
use
standard
definit
hospitalacquir
infect
although
could
overestim
rate
rv
nosocomi
acquisit
window
conclus
ltr
incid
rv
infect
high
rv
associ
signific
clinic
impact
picornavirus
frequent
encount
rv
main
caus
urtid
lrtid
tracheobronch
asymptomat
infect
wherea
lrtid
pneumonia
caus
paramyxoviru
influenza
viru
result
higher
hospit
rate
rv
infect
associ
immedi
allograft
dysfunct
assess
spirometri
outcom
rv
produc
local
system
mdim
contribut
significantli
ar
p
aeruginosa
colon
infect
cmv
replic
diseas
data
highlight
import
infect
control
mitig
nosocomi
infect
highrisk
patient
popul
